Topics

Darolutamide Nears EU Approval for Nonmetastatic CRPC

16:04 EST 31 Jan 2020 | OncLive

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease.

Original Article: Darolutamide Nears EU Approval for Nonmetastatic CRPC

NEXT ARTICLE

More From BioPortfolio on "Darolutamide Nears EU Approval for Nonmetastatic CRPC"

Quick Search

Relevant Topic

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...